JPRN-UMIN000017037
Completed
Phase 3
The study for the effect of intravitreous injection of ranibizumab (product name: Lucentis) and subthreshold laser photocoagulation on diabetic macular edema - The study for the effect of combination therapy of intravitreous injection of ranibizumab and subthreshold laser photocoagulation on diabetic macular edema
Conditionsdiabetic macular edema
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- diabetic macular edema
- Sponsor
- Jichi Medica University, Saitama Medical Center
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who receive occular surgical treatments within 3 months Patients who receive other macular diseases
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Intravitreal injection of methotrexate in persistent diabetic macular edemaResistant macular edema in diabetic patients.Distrubtion of retinal layers due to edemaIRCT201610098983N2Guilan University of Medical Sciences,Vice chancellor for research42
Recruiting
Phase 1
Comparison of the effect of intravitreal injection of bevacizumab (Stevenet) alone with intravitreal injection of bevacizumab and triamcinolone in the treatment of diabetic macular edema with a thickness greater than 500 microns in patientsIRCT20211130053229N1Kerman University of Medical Sciences70
Recruiting
Phase 1
Investigating the effect of mesenchymal stem cell injection on reducing complications in patients with liver cirrhosisReducing complications of liver failure in patients with decompensated liver cirrhosis.Congenital cirrhosis (of liver)P78.81IRCT20140911019125N11Kerman University of Medical Sciences10
Active, not recruiting
Not Applicable
Funktionelle Ergebnisse der intravitrealen Injektion von Triamcinolonacetonid im Vergleich zur konventionellen Lasertherapie bei diabetischem Makulaödem. - DME-TAEUCTR2004-005197-23-DEKlinik und Poliklinik für Augenheilkunde der Universität Regensburg40
Completed
Not Applicable
complications of injection given in the eye for retinal diseasesHealth Condition 1: null- healthy patients who had given intravitreal bevacizumab for ocular problemCTRI/2015/10/006250ETHRADHAMA SUPERSPECIALITY EYE HOSPITA100